Moderna Inc. [NASDAQ: MRNA] loss -3.58% or -4.64 points to close at $125.01 with a heavy trading volume of 16499226 shares. The company report on January 12, 2021 that José M. Vega, M.D. Joins Moderna as Chief Safety Officer.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that José M. Vega, M.D. joined Moderna as Chief Safety Officer effective Monday, January 11, 2021. Dr. Vega will report to Chief Medical Officer Tal Zaks, M.D., Ph.D.
“José brings a strategic level of leadership and deep experience in drug development and pharmacovigilance in global biopharmaceutical companies including Merck and Amgen,” said Dr. Zaks. “I am thrilled to welcome José to the Moderna team as we enter the next phase of growth of our company.”.
It opened the trading session at $122.10, the shares rose to $126.36 and dropped to $120.50, the range by which the price of stock traded the whole day. The daily chart for MRNA points out that the company has recorded 51.20% gains over the past six months. However, it is still -597.99% lower than its most recent low trading price.
If we look at the average trading volume of 22.57M shares, MRNA reached to a volume of 16499226 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $141.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 16, 2020. While these analysts kept the previous recommendation, Jefferies dropped their target price from $90 to $150. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock.
The Average True Range (ATR) for Moderna Inc. is set at 9.79, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 200.62. The Price to Book ratio for the last quarter was 17.88, with the Price to Cash per share for the same quarter was set at 8.28. Price to Free Cash Flow for MRNA in the course of the last twelve months was 80.75 with Quick ratio for the last quarter at 2.40.
Trading performance analysis for MRNA stock
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.61. With this latest performance, MRNA shares dropped by -8.77% in over the last four-week period, additionally plugging by 51.20% over the last 6 months – not to mention a rise of 506.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 51.88, with the RSI for the last a single of trading hit 52.83, and the three-weeks RSI is set at 52.67 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 120.14, while it was recorded at 126.60 for the last single week of trading, and 78.20 for the last 200 days.
Moderna Inc. [MRNA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -906.38. Moderna Inc.’s Net Margin is presently recorded at -853.73.
Return on Total Capital for MRNA is now -37.83, given the latest momentum, and Return on Invested Capital for the company is -35.81. Return on Equity for this stock declined to -38.00, with Return on Assets sitting at -28.95. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 11.57. Additionally, MRNA Total Debt to Total Capital is recorded at 10.37, with Total Debt to Total Assets ending up at 8.55. Long-Term Debt to Equity for the company is recorded at 11.27, with the Long-Term Debt to Total Capital now at 10.10.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$619,302 per employee. Receivables Turnover for the company is 2.57 with a Total Asset Turnover recorded at a value of 0.03.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Moderna Inc. [MRNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Moderna Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
An analysis of insider ownership at Moderna Inc. [MRNA]
There are presently around $25,347 million, or 52.00% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: FMR LLC with ownership of 34,221,324, which is approximately -8.821% of the company’s market cap and around 2.10% of the total institutional ownership; FLAGSHIP PIONEERING INC., holding 30,871,524 shares of the stock with an approximate value of $3.86 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $3.48 billion in MRNA stock with ownership of nearly 8.779% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 360 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 14,918,678 shares. Additionally, 212 investors decreased positions by around 29,182,555 shares, while 50 investors held positions by with 158,661,216 shares. The mentioned changes placed institutional holdings at 202,762,449 shares, according to the latest SEC report filing. MRNA stock had 145 new institutional investments in for a total of 1,846,454 shares, while 71 institutional investors sold positions of 3,714,894 shares during the same period.